Benitec Biopharma Limited (Benitec) is an Australia-based company engaged in progressing its programs through the clinic, the commercialization of the Company's intellectual property (IP), development of its therapeutic pipeline and pre-clinical programs, funding, and protection and building the IP estate. The Company has a pipeline of in-house and partnered therapeutic programs based on its gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid (RNA) interference (ddRNAi). It is engaged in developing treatments for chronic human conditions, such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, it has licensed its ddRNAi technology to other biopharmaceutical companies, including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS), retinitis pigmentosa and Huntington's disease.